Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2021 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
September 01, 2021 07:00 ET | Source: Arvinas Inc.

Arvinas to Participate in Upcoming Virtual Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
August 05, 2021 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
July 22, 2021 07:00 ET | Source: Arvinas Inc.

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2...
June 07, 2021 17:19 ET | Source: Arvinas Inc.

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
June 03, 2021 07:00 ET | Source: Arvinas Inc.

Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference

NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
May 20, 2021 16:30 ET | Source: Arvinas Inc.

Arvinas to Present at the UBS Global Healthcare Virtual Conference

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
May 04, 2021 14:52 ET | Source: Arvinas Inc.

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
May 04, 2021 07:00 ET | Source: Arvinas Inc.

Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today...
April 05, 2021 16:30 ET | Source: Arvinas Inc.

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right